NEW YORK – Danaher announced Tuesday that its European subsidiary priced an offering of €6.2 billion ($6.83 billion) in senior notes due between 2026 and 2049.
The company will offer €1.25 billion of .2 percent senior notes due in 2026; €1.25 billion of .45 percent senior notes due in 2028; €1.75 billion of .75 percent senior notes due in 2031; €1.25 billion of 1.35 percent senior notes due in 2039; and €750 million of 1.8 percent senior notes due in 2049.
The Washington, DC-based conglomerate said in a statement it plans to use the money to fund part of the cash consideration and other costs associated with its planned $21.4 billion acquisition of GE Life Sciences' Biopharma business. Danaher also said it may invest the proceeds in short-term bank deposits or investment-grade securities.
The company expects the offering to close on Sept. 18, 2019.